Press release
Mucopolysaccharidosis Treatment Market Outlook 2025 to 2035 Growth Insights by Sangamo Therapeutics, Inc., REGENXBIO Inc., Orchard Therapeutics Limited
Mucopolysaccharidosis Treatment Market
Click Here for More Information:- https://www.futuremarketinsights.com/reports/mucopolysaccharidosis-treatment-market
Key Growth Drivers and Innovations
Advancements in biotechnology, improved diagnostic techniques facilitating early detection, and increased awareness of rare diseases are significantly boosting treatment adoption. The availability of ERT and ongoing research into curative gene therapies enhance treatment outcomes and patient quality of life. Pharmaceutical manufacturers are also collaborating with healthcare institutions to address unmet patient needs, further propelling market expansion.
Prevalence, Screening, and Treatment Uptake
MPS exhibits a global birth prevalence of approximately 1.56 per 100,000 live births, with MPS II often showing the highest subtype prevalence in many regions. While diagnostic delays persist, time to first treatment is improving in countries like the UK. For MPS I (Hurler), HSCT is the standard for children under 2-2.5 years, while ERT remains the default for other subtypes, with uptake defining coverage trends.
Market Performance and Half-Year Trends
The global MPS treatment market recorded a 5.2% CAGR from 2020 to 2024, with sales reaching USD 2,669.1 million in 2024. For 2025 to 2035, the market is predicted to grow at a 5.9% CAGR. Semi-annual projections show the H1 (2025-2035) CAGR at 5.9%, slightly decreasing to 5.4% in H2, reflecting minor shifts in market performance.
Strategic Growth Initiatives
Increased R&D investment by pharmaceutical companies is driving the development of more effective and targeted treatments, including advanced ERTs and potential gene therapies aiming for cures. For instance, REGENXBIO Inc. announced positive Phase III trial results for RGX-121 for MPS II in February 2024. Strategic acquisitions, like Kyowa Kirin Co., Ltd.'s acquisition of Orchard Therapeutics plc in January 2024, are expanding drug pipelines. Companies are also exploring combination therapies that target multiple disease facets, potentially offering more comprehensive and curative solutions, enhancing product uniqueness and market leadership.
Overcoming Cost Barriers
High treatment costs pose a significant challenge to MPS treatment adoption and market growth. ERT, gene therapies, and stem cell transplants are often expensive, creating financial burdens for patients and healthcare systems. These high costs limit patient access, especially in low- and middle-income countries, and can deter healthcare providers and insurers from widespread adoption, thus impacting early diagnosis and treatment.
Get Sample Report: - https://www.futuremarketinsights.com/reports/sample/rep-gb-5880
Competitive Tier Analysis
The MPS treatment market features a stratified competitive landscape. Tier 1 companies, including BioMarin Pharmaceutical, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Sumitomo Pharma Co., Ltd., command 68.6% of the global market with extensive product portfolios and broad geographical reach. Tier 2 companies, such as Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Sangamo Therapeutics, Inc., and JCR Pharmaceuticals, hold a 26.6% market share, demonstrating strong regional presence. Tier 3 companies act as specialized suppliers. Recent developments include JCR Pharmaceuticals and MEDIPAL HOLDINGS CORPORATION's Phase I/II clinical trial for JR-446 for MPS IIIB in December 2024, and JCR's co-promotion agreement with Sumitomo Pharma for IZCARGO in April 2023.
Key Regional Market Trends
The United States (7.4% CAGR) leads North America, driven by the FDA's focus on orphan drug designations, providing incentives for pharmaceutical companies to accelerate innovative therapies. Japan (6.3% CAGR) emphasizes new product launches, with manufacturers like Ultragenyx Pharmaceutical Inc. introducing new drugs for conditions such as MPS VII (e.g., in September 2022), improving patient outcomes and fostering innovation. The UK (5.4% CAGR) benefits from strategic collaborations between research institutes and hospitals, such as The University of Manchester's clinical trial for AVR-RD-05 for neuronopathic MPS II, which accelerates new treatment development and ensures faster market access. Other significant growth is observed in Germany (7.1% CAGR), China (4.1% CAGR), India (3.7% CAGR), and Australia (5.2% CAGR).
Discover Related Research:-
Vaginitis Treatment Drug Market
https://www.futuremarketinsights.com/reports/vaginitis-treatment-drugs-market
Atherosclerosis Market
https://www.futuremarketinsights.com/reports/atherosclerosis-market
Mucopolysaccharidosis Treatment Market
https://www.futuremarketinsights.com/reports/mucopolysaccharidosis-treatment-market
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Treatment Market Outlook 2025 to 2035 Growth Insights by Sangamo Therapeutics, Inc., REGENXBIO Inc., Orchard Therapeutics Limited here
News-ID: 4123899 • Views: …
More Releases from Future Market Insights Inc
Oatmeal Market Soars, Forecast to Reach USD 11129.4 Million by 2035 Amid Health …
The global oatmeal market, valued at USD 6,378.3 million in 2025, is poised for remarkable growth, with a new market outlook forecasting it to reach USD 11,129.4 million by 2035. Driven by a robust Compound Annual Growth Rate (CAGR) of 5.7%, this expansion is fueled by a powerful convergence of consumer trends, including a heightened focus on health, the demand for convenience, and a shift toward sustainable and plant-based diets.
The…
Native Starch Market to Reach USD 2.9 Billion by 2035, Driven by Clean-Label and …
The global native starch market is on a robust growth trajectory, propelled by the worldwide movement toward clean-label and minimally processed ingredients. Valued at USD 1.8 billion in 2025, the market is forecasted to expand to USD 2.9 billion by 2035, with a healthy Compound Annual Growth Rate (CAGR) of 5.7%. This significant growth underscores native starch's critical role in meeting evolving consumer demands for healthier, more natural food and…
Microbial Seed Treatment Market to Grow at 12.8% CAGR, Reaching USD 4.47 Billion …
The global microbial seed treatment market is poised for significant growth, with a new market outlook forecasting a robust compound annual growth rate (CAGR) of 12.8% from 2025 to 2035. Valued at an estimated USD 1.34 billion in 2025, the market is projected to reach an impressive USD 4.47 billion by 2035, reflecting a dramatic shift towards eco-friendly and high-performance agricultural solutions.
This surge is fueled by a combination of…
Potash Ores Market to Reach USD 2.3 Billion by 2035, Driven by Agricultural Dema …
The global potash ores market, a vital component of the agricultural and industrial sectors, is set for robust expansion, with its value projected to grow from an estimated USD 1.6 billion in 2025 to USD 2.3 billion by 2035. This represents a steady Compound Annual Growth Rate (CAGR) of 3.5%, according to a new market analysis. The consistent growth is primarily fueled by the accelerating global demand for food, which…
More Releases for MPS
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Modular Panelboard System (MPS) Market 2022 | Detailed Report
Global Modular Panelboard System (MPS) Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5256552
The report…
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.
Download the sample report @ https://www.pharmaproff.com/request-sample/1146
In later stages of this disorder, people…
Managed Print Services (MPS) Market Experience A Tremendous growth in future
HTF MI recently introduced Global Managed Print Services (MPS) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Xerox Corporation, HP, Canon, Ricoh, Lexmark, Konica Minolta Inc.,…
ROTOCONTROL Appoints MPS Systems UK as Agent in United Kingdom
Trittau, Germany (July 18, 2013) – ROTOCONTROL, a manufacturer of leading-edge slitter/rewinder inspection machines today announced the appointment of MPS Systems UK as the ROTOCONTROL/LeoMat agent in the United Kingdom. MPS Systems UK, a subsidiary of the Dutch MPS Systems B.V., will now offer the ROTOCONTROL/LeoMat brand of leading-edge finishing machines for inspection, slitting, rewinding, die cutting, overprinting, digital labels and booklet labels for converters throughout the United Kingdom.
Led by…
Data8 to offer unlimited TPS, CTPS and MPS screening licences
Data8, the premier data enrichment specialist, have today announced that they will offer unlimited licenses to large volume TPS (Telephone Preference Service), CTPS (Corporate Telephone Preference Service) and MPS (Mail Preference Service) users. By removing the royalty fee structure, data8 believe it will encourage wide spread adoption by clients of these data files.
Antony Allen, managing director data8, “I am pleased to announce today that from 1st February 2012 we…
